FDA Rejects Summit's Ivonescimab Filing; AstraZeneca Partnership Setback
Published 2 d ago2 sourcesEvidence: Reported
Brazil's ANS will require health plans to cover a molecular test and a cancer drug for patients with a specific mutation, expanding mandatory coverage. The move improves access to precision oncology but its cost impact on insurers is unclear. This is a regulatory change in Brazil's private healthcare market.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 9 h ago1 sourceEvidence: Reported
Published 2 d ago4 sourcesEvidence: Reported
Published 1 d ago11 sourcesEvidence: Reported
Published 1 d ago7 sourcesEvidence: Reported
Published 2 d ago3 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported